1. Home
  2. AMAL vs MGTX Comparison

AMAL vs MGTX Comparison

Compare AMAL & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amalgamated Financial Corp. (DE)

AMAL

Amalgamated Financial Corp. (DE)

HOLD

Current Price

$50.42

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$12.54

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMAL
MGTX
Founded
1923
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
AMAL
MGTX
Price
$50.42
$12.54
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$36.00
$24.57
AVG Volume (30 Days)
145.5K
649.1K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
1.68%
N/A
EPS Growth
N/A
33.02
EPS
1.99
N/A
Revenue
N/A
$81,391,000.00
Revenue This Year
$21.18
$141.38
Revenue Next Year
$6.55
N/A
P/E Ratio
$25.03
N/A
Revenue Growth
N/A
144.57
52 Week Low
$25.13
$6.62
52 Week High
$50.92
$15.35

Technical Indicators

Market Signals
Indicator
AMAL
MGTX
Relative Strength Index (RSI) 67.24 54.41
Support Level $36.50 $7.04
Resistance Level $50.92 $15.35
Average True Range (ATR) 1.13 0.58
MACD 0.04 -0.08
Stochastic Oscillator 83.61 73.58

Price Performance

Historical Comparison
AMAL
MGTX

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: